AstraZeneca Revises Covid Vaccine Following Massive Criticism; Here Are The Results

AstraZeneca Revises Covid Vaccine Following Massive Criticism; Here Are The Results
SHARE

As you probably know by now, there have been all kinds of issues with the AstraZeneca vaccine. It’s been reported that more European nations and one in Asia suspended the use of AstraZeneca’s covid vaccine. You are probably aware that this has been happening due to safety fears following some pretty severe health issues and even deaths after the vaccine. WHO recently responded. 

Now, CNBC notes that AstraZeneca issued an updated phase three trial data for the vaccine just the other day, following accuracy questions.

New results are out 

The firm now said that the vaccine is 76% effective in protecting against the symptomatic cases of the virus. 

The updated report maintains that the shot is 100% effective against severe disease and hospitalization, according to CNBC.

It’s been also reported that there are some US health official who criticized the company recently for what some have been claiming was data cherry-picking to make the results seem more favourable. 

The National Institute of Allergy and Infectious Diseases revealed on Tuesday it had been informed the U.K.-based company may have included information from its U.S. results that provided an “incomplete view of the efficacy data.”

AstraZeneca said back then that the figures were based on a “pre-specified interim analysis” and vowed to share updated analysis in the coming days.

“This is really what you call an unforced error because the fact is this is very likely a very good vaccine,” Fauci told ABC’s Robin Roberts on “Good Morning America” on Tuesday.

He continued and said: “This kind of thing does … really cast some doubt about the vaccines and maybe contribute to the hesitancy. It was not necessary.”

It’s also important to note the fact that the updated results include data collected from 190 symptomatic cases, across more than 32,000 participants – in other words, this means an increase of roughly 50 symptomatic cases studied compared with the data set that has been released on Monday.


SHARE

Share this post

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.